GCG and metabolic disease: Studies have shown that ADCY8 induces innate immune-associated antiviral host defense in response to macrophage SCN5A (Jones et al., 2014), and ADCY8 also affects glucagon-like peptide 1 signaling and glucose levels in metabolic diseases (Roger et al., 2010).